|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Jakub Julian Baran||Chairman of the Management Board & CEO||N/D||N/D||N/D|
|Mr. Tomasz Franciszek Baran||Vice President of the Management Board & Chief Commercial Officer||N/D||N/D||N/D|
|Mr. Dirk Plaga||CFO & Member of Management Board||N/D||N/D||1965|
|Santiago Luengo||Managing Director of Secuvita||N/D||N/D||N/D|
VITA 34 AG engages in the collection, processing, and cryopreservation of stem cells from umbilical cord blood and tissue in Germany, Poland, Portugal, and internationally. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces viral vectors and CAR-T cells. The company manufactures advanced therapy medicinal products for third parties. In addition, it offers a range of products for long-term storage of biological material obtained at birth, as well as placental blood or umbilical cord tissue or placenta tissue. Further, the company provides sperm banking services for freezing sperm; adipose tissue banking services as a source of mesenchymal stem cells and stromal vascular fraction; medical consultations and non-diagnostic ultrasound examination services; and other contract manufacturing services for classical transplantations or cell and gene therapies. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
L'ISS Governance QualityScore di VITA 34 AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.